Skip to main content
. 2020 Jun;9(3):803–806. doi: 10.21037/tlcr-20-517

Figure 3.

Figure 3

Plasma tumor markers levels during neoadjuvant chemo-immunotherapy. The plasma levels of the tumor markers CEA, CyFra21-1, and NSE were elevated at the time of initial diagnosis. All of them had decreased to normal levels after the first cycle of neoadjuvant chemo-immunotherapy and continued decreasing after the second cycle of neoadjuvant treatment. The plasma levels of the tumor markers SCC and CA125 were normal and stable during the neoadjuvant treatment period. RR, reference range.